InvestorsHub Logo
Followers 167
Posts 9335
Boards Moderated 0
Alias Born 08/07/2013

Re: Timing101 post# 42074

Tuesday, 11/10/2020 9:59:33 AM

Tuesday, November 10, 2020 9:59:33 AM

Post# of 198805
It is almost time to buckle up folks!


Charles Cotropia, CEO of Enzolytics, stated, "The addition of a professional of the caliber of Dr. Moss to the team of professionals with Enzolytics adds significant expertise to our progress toward realizing the full potential of combining the anti-HIV technology of BioClonetics with that of Enzolytics' ITV-1 Peptide therapeutic."

The Company has also procured a commitment for funding of $500,000.00 and has received the first tranche of $250,000. These funds are earmarked for implementation of the planned combined operations and the initial steps of the merged business strategy of creating successful therapeutics against infectious diseases thereby increasing the value of the Company's extensive technology. The second Tranche of funding will be received upon completion of the business combination documents. As part of the initial $500,000.00 funding, the Company and certain of its current convertible debt holders have agree to a 30-day standstill on issuance of any additional shares from conversions of debt.

Enzolytics has begun the process of bringing its filings current having filed the September 30, 2018, December 31, 2018 and March 31, 2019 reports.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENZC News